These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 7138571

  • 1. Spectral interaction of orphenadrine and its metabolites with oxidized and reduced hepatic microsomal cytochrome P-450 in the rat.
    Bast A, Noordhoek J.
    Biochem Pharmacol; 1982 Sep 01; 31(17):2745-53. PubMed ID: 7138571
    [No Abstract] [Full Text] [Related]

  • 2. Product inhibition in orphenadrine metabolism as a result of a stable cytochrome P-450-metabolic intermediate complex formed during the disposition of mono-N-desmethylorphenadrine (tofenacine) in the rat.
    Bast A, van Kemenade FA, Savenije-Chapel EM, Noordhoek J.
    Res Commun Chem Pathol Pharmacol; 1983 Jun 01; 40(3):391-403. PubMed ID: 6622816
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of oxidative drug metabolism by orphenadrine: in vitro and in vivo evidence for isozyme-specific complexation of cytochrome P-450 and inhibition kinetics.
    Reidy GF, Mehta I, Murray M.
    Mol Pharmacol; 1989 May 01; 35(5):736-43. PubMed ID: 2725477
    [Abstract] [Full Text] [Related]

  • 4. Relationship between molecular structure and cytochrome P450-metabolic intermediate complex formation, studied with orphenadrine analogues.
    Bast A, Savenije-Chapel EM, Noordhoek J.
    J Pharm Sci; 1984 Jul 01; 73(7):953-6. PubMed ID: 6470960
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Metabolite complex formation of orphenadrine with cytochrome P450. Involvement of CYP2C11 and CYP3A isozymes.
    Roos PH, Mahnke A.
    Biochem Pharmacol; 1996 Jul 12; 52(1):73-84. PubMed ID: 8678911
    [Abstract] [Full Text] [Related]

  • 8. Interaction of nitromethane with reduced hepatic microsomal cytochrome P-450.
    Wade AE, Evans JS, Sternson LA, Gammans RE.
    Biochem Pharmacol; 1977 May 15; 26(10):963-7. PubMed ID: 16606
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The role of oxygenated cytochrome P-450 and of cytochrome b5 in hepatic microsomal drug oxidations.
    Baron J, Hildebrandt AG, Peterson JA, Estabrook RW.
    Drug Metab Dispos; 1973 May 15; 1(1):129-38. PubMed ID: 4149374
    [No Abstract] [Full Text] [Related]

  • 13. Evidence for the stability and cytochrome P450 specificity of the phenobarbital-induced reductive halothane-cytochrome P450 complex formed in rat hepatic microsomes.
    Baker MT, Vasquez MT, Chiang CK.
    Biochem Pharmacol; 1991 Jun 01; 41(11):1691-9. PubMed ID: 2043158
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The interaction of vinyl chloride with rat hepatic microsomal cytochrome P-450 in vitro.
    Ivanetich KM, Aronson I, Katz ID.
    Biochem Biophys Res Commun; 1977 Feb 21; 74(4):1411-8. PubMed ID: 14640
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.